𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial

✍ Scribed by Kalanithi Nesaretnam; Kanga Rani Selvaduray; Ghazali Abdul Razak; Sheela Devi Veerasenan; Patricia A Gomez

Book ID
119915576
Publisher
BioMed Central
Year
2010
Tongue
English
Weight
656 KB
Volume
12
Category
Article
ISSN
1465-5411

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A randomized trial of tamoxifen alone or
A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma
✍ James N. Ingle; Vera J. Suman; Carl G. Kardinal; James E. Krook; James A. Mailli πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 110 KB πŸ‘ 2 views

## BACKGROUND. Tamoxifen (TAM) is generally considered the hormonal agent of choice for postmenopausal women with hormone receptor positive breast carcinoma. The somatostatin analogues, including octreotide, have demonstrated inhibition of breast carcinoma cell lines and multiple endocrinologic act

Anastrozole alone or in combination with
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses
✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 120 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d